#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening


Authors: Dana Tomčíková;  Zuzana Prepiaková;  Beáta Bušányová;  Barbora Kostolná
Authors place of work: University and the National Institute of Children’s Diseases, Bratislava, Slovakia ;  Department of Pediatric Ophthalmology, Faculty of Medicine of Comenius
Published in the journal: Čes. a slov. Oftal., 81, 2025, No. Ahead of Print, p. 1-5
Category: Původní práce
doi: https://doi.org/10.31348/2025/23

Summary

Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.

Keywords:

recurrence of ROP – ROP recurrence screening – intravitreal treatment of ROP – follow-up monitoring of premature infants with ROP – ROP screening


Štítky
Oftalmológia

Článok vyšiel v časopise

Česká a slovenská oftalmologie

Číslo Ahead of Print

2025 Číslo Ahead of Print
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#